AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KYMR

BVF PARTNERS L P/IL sold $5.5M of KYMR (indirect holdings)

BVF PARTNERS L P/IL sold 51,858 indirectly-held shares of Kymera Therapeutics, Inc. (KYMR) at $106.50 ($5.52M total) on 2026-06-26.

Original reporting
SEC EDGAR · BVF PARTNERS L P/IL
Published Jun 26, 2026, 10:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KYMR
Neutral
low confidence
Mentioned
$KYMR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KYMRNeutralLow
01

Why it matters

The newest fact is the same-day open-market sale by a director via an indirect holding, totaling about $5.52M at $106.50/share.

02

Market read

Useful for tracking insider behavior, but it does not introduce new operational/financial guidance or regulatory/clinical catalysts.

03

What to watch

No 10b5-1 plan is stated, but the article also provides no context for why the sale occurred; traders should wait for additional insider buys/sells or company-specific news.

Relevance 6/10Novelty 5/10Timing: filed 2026-06-26 (after-hours) for an insider sale executed the same day

Background

This is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, Inc.

Company-level read

Ticker impact

$KYMRNeutralLow confidence
Context

Kymera Therapeutics disclosed a Form 4: BVF Partners L P/IL (director) sold 51,858 shares at $106.50 on 2026-06-26 via an open-market sale.

Expected impact

Likely limited, short-lived impact; watch for follow-through in subsequent insider filings rather than a directional move.

Evidence & confidence

Form 4 insider sales can be routine and are not accompanied here by new company fundamentals; the filing provides timing and size but no stated reason or guidance change.

Market effects

Sector

Minimal read-across; this is a single-company insider transaction with no sector-wide catalyst.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

The sale may be unrelated to fundamentals (liquidity/tax/portfolio rebalancing), especially since the filing does not indicate any adverse company event.

Key entities

  • issuer
    Kymera Therapeutics, Inc.

    Subject of the Form 4 insider transaction; director-related indirect holdings were reduced via an open-market sale.

  • insider
    BVF Partners L P/IL

    Reporter on the Form 4; director role and sold 51,858 shares at $106.50 on 2026-06-26.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KYMR insider trading history →

Related articles

$KYMRMed

Kymera (KYMR) Q3 2026 Earnings Call Transcript

Kymera (KYMR) reported Q3 2026 earnings, highlighting progress in its pipeline, including Phase IIb data for KT-621 in atopic dermatitis (AD) expected by year-end. The BROADEN 2 study's placebo-controlled portion is complete, with 98% of eligible patients enrolling in the open-label extension. The company also discussed market research indicating a demand for safe, effective oral treatments for AD.

finance.yahoo.com
$KYMRMed

Kymera Therapeutics Q3 Earnings Call Highlights

Kymera Therapeutics reported Q3 results, highlighting 98% inhibition of TLR7/8-stimulated interferon-beta levels and positive phase I data for KT-579. The company plans a phase Ib lupus study (LUMORA) in early 2027. KT-621 is expected to show atopic dermatitis efficacy comparable to dupilumab. Q3 R&D expenses were $128.5M, with cash position of $1.6B providing runway into 2029.

finance.yahoo.com
$KYMRMedAI 8/10

Kymera Q3 2026 slides: IRF5 degrader shows 90%+ target engagement

Kymera Therapeutics (KYMR) reported Q3 2026 results, missing earnings but showing 90%+ target engagement for its IRF5 degrader KT-579. The stock rose 3.46% premarket. The company reported a net loss of $132M, up from $82.2M YoY, with R&D expenses increasing 73%. Kymera has $1.6B in cash, providing a runway into 2029. KT-579 showed promising Phase 1 data, with significant biomarker reductions and a favorable safety profile.

investing.com
$KYMRHigh

Kymera Therapeutics 3Q 2026: Revenue $0 Net loss $132M, EPS $(1.32) — 10-Q Summary

Kymera Therapeutics reported 3Q 2026 revenue of $0, down from $2.8M a year earlier, and a net loss of $132M, or $(1.32) per share, compared to a net loss of $82.2M, or $(0.94) per share, in the prior-year quarter. The company's collaboration revenue for the nine months increased to $99.4M, driven by partnerships with Gilead and Sanofi. Research and development spending rose 49%, primarily due to expanded program work and personnel investments.

tradingview.com
$KYMRHighAI 8/10

Kymera reports phase 1 data for KT-579, plans lupus trial

Kymera Therapeutics (KYMR) reported phase 1 trial results for KT-579, showing significant IRF5 degradation and biomarker reductions. The company plans a phase 1b lupus trial in 2027. Q3 2026 net loss was $132.0M, up from $82.2M in 2025, with R&D expenses increasing. Cash reserves are $1.6B, expected to last into 2029. Updates on other clinical trials were also provided.

investing.com